Search results for "double-blind"

showing 10 items of 662 documents

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available s…

2015

Edward M Wolin,1 Barbara Jarzab,2 Barbro Eriksson,3 Thomas Walter,4 Christos Toumpanakis,5 Michael A Morse,6 Paola Tomassetti,7 Matthias M Weber,8 David R Fogelman,9 John Ramage,10 Donald Poon,11 Brian Gadbaw,12 Jiang Li,12 Janice L Pasieka,13 Abakar Mahamat,14 Fredrik Swahn,15 John Newell-Price,16 Wasat Mansoor,17 Kjell Öberg3 1Markey Cancer Center, University of Kentucky, Lexington, KY, USA; 2Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland; 3Department of Medical Sciences, Endocrine Oncology Unit, University Hospital, Uppsala, Sweden; 4Department of Medical Oncology, Ed…

MaleTime FactorsPharmaceutical ScienceOctreotideKaplan-Meier EstimateNeuroendocrine tumorsDigestive System NeoplasmsOctreotideGastroenterologychemistry.chemical_compoundDrug DiscoveryOdds RatioOriginal ResearchAged 80 and oversomatostatin analoguesDrug SubstitutionHazard ratioMiddle AgedTumor BurdenTreatment OutcomeFemalemedicine.symptomSomatostatinCarcinoid syndromemedicine.drugAdultmedicine.medical_specialtyNauseaCarcinoid tumorscarcinoid syndromeAntineoplastic AgentsCarcinoid TumorDisease-Free SurvivalDouble-Blind MethodInternal medicinemedicineHumansProgression-free survivalAgedProportional Hazards ModelsPharmacologypasireotideCancer och onkologiDrug Design Development and Therapybusiness.industrylcsh:RM1-950medicine.diseasesymptom controlPasireotidelcsh:Therapeutics. PharmacologyEndocrinologyLogistic ModelschemistryDrug Resistance NeoplasmDelayed-Action PreparationsCancer and Oncologyneuroendocrine tumorsbusinessprogression-free survival
researchProduct

Immunogenicity of reduced antigen content tetanus–diphtheria–acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pert…

2006

Three hundred and nineteen adolescents aged 10-12 years who had been previously vaccinated with five doses of acellular pertussis-containing vaccines received single doses of Tdap (reduced-antigen-content tetanus, diphtheria, acellular pertussis) and hepatitis A vaccines in a double-blind crossover trial. Long-term antibody persistence following vaccination with Tdap at pre-school age was similar to that following vaccination with DTaP (diphtheria-tetanus-acellular pertussis). After the sixth dose booster, Tdap induced a vigorous immune response, consistent with protection against diphtheria, tetanus and pertussis diseases.

MaleTime FactorsWhooping CoughHepatitis A vaccineImmunization SecondaryBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesDouble-Blind MethodmedicineHumansChildWhooping coughAntigens BacterialHepatitis A VaccinesTetanusGeneral VeterinaryGeneral Immunology and MicrobiologyTetanusbusiness.industryImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthDiphtheriamedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationImmunologyMolecular MedicineFemalebusinessVaccine
researchProduct

An evaluation of the efficacy of a topical gel with Triester Glycerol Oxide (TGO) in the treatment of minor recurrent aphthous stomatitis in a Turkis…

2017

Background Triester glycerol oxide gel (Protefix® Queisser Pharma, Germany) is a new topical agent that has the property of adherence to the oral mucosa by forming a lipid film which protects against mechanical trauma and may help to reduce oral tissue moisture loss and inflammation. The aim of this clinical trial was to determine the efficacy of a topical TGO gel and to also compare it with triamcinolone acetonide pomade in the treatment of minor recurrent aphthous stomatitis. Material and Methods This study was a randomized, double-blind, placebo-controlled clinical trial and 180 patients with the complaint of minor aphthous ulcers were enrolled in this study. The sociodemographic data an…

MaleTriamcinolone acetonideTurkeyAdministration TopicalTABLETStriamcinolone acetonideminor recurrent aphthous stomatitisDISEASEOintmentsULCERATION0302 clinical medicineRecurrenceOral mucosaYoung adultMiddle Aged:CIENCIAS MÉDICAS [UNESCO]030205 complementary & alternative medicineTreatment Outcomemedicine.anatomical_structureULCERSCohortUNESCO::CIENCIAS MÉDICASTopical therapyFemaleStomatitis Aphthousmedicine.drugAdultmedicine.medical_specialtyAdolescentRecurrent aphthous stomatitisPlaceboDouble blindYoung Adult03 medical and health sciencesDouble-Blind MethodInternal medicinemedicinetriester glycerol oxideMANAGEMENTHumansGlucocorticoidsGeneral DentistryAgedOral Medicine and Pathologybusiness.industryResearch030206 dentistrySurgeryClinical trialOtorhinolaryngologySurgeryLASERbusinessGelsPASTE
researchProduct

Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy

2016

Background and objective: Statin-induced myopathy (SIM) has been partially attributed to deficiency of dolichol and coenzyme Q10 (CoQ10). We aimed to test the safety and efficacy of plant polyprenols in combination with CoQ10 for alleviation of SIM. Materials and methods: In an open-label, one-center prospective pilot study patients with SIM received conifer-tree needle polyprenols (4 mg/day) and CoQ10 (100 mg/day) for 8 weeks. Symptoms and safety were evaluated according to symptom severity score (0–10), creatine kinase (CK) levels, exercise test, dynamometry, complete blood count, clinical biochemistry and electrocardiography. Results: Of the 14 patients, 11 completed the study per protoc…

MaleUbiquinoneMyopathyPilot Projects030204 cardiovascular system & hematologyGastroenterologyElectrocardiography0302 clinical medicine030212 general & internal medicineProspective StudiesProspective cohort studyPain MeasurementAged 80 and overMedicine(all)lcsh:R5-920Muscle Weaknessbiologymedicine.diagnostic_testComplete blood countMiddle AgedTreatment OutcomeDrug Therapy CombinationFemalemedicine.symptomlcsh:Medicine (General)Glomerular Filtration Ratemedicine.medical_specialtyStatinmedicine.drug_classRenal functionAsymptomaticPolyprenols03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMyopathyAgedbusiness.industryTerpenesStatinsMyalgiamedicine.diseaseTracheophytaAutomotive EngineeringPhysical therapybiology.proteinExercise TestCoenzyme Q10Creatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessStatins; Myopathy; Polyprenols; Coenzyme Q10; UbiquinoneBiomarkersKidney diseaseMedicina
researchProduct

Is Dexamethasone superior to Ketorolac in reducing pain, swelling and trismus following mandibular third molar removal? A split mouth triple-blind ra…

2021

Background The preemptive use of anti-inflammatory drugs, such as corticosteroids and NSAIDs, has the potential to reduce pain, swelling and trismus following oral surgery. The aim of this study was to compare the efficacy of dexamethasone and ketorolac tromethamine in reducing pain, swelling and trismus after mandibular third molar removal. Material and Methods The researches implemented a triple-blind, randomized clinical trial. The study was conducted with ASA I individuals aging between 18 and 35 years, which were randomized and submitted to two interventions, one with 8mg dexamethasone and the other with 20mg ketorolac tromethamine given 1h before the procedure. The primary predictor v…

MaleVisual analogue scaleAnalgesicTrismusKetorolac TromethamineDexamethasonelaw.inventionRandomized controlled trialDouble-Blind MethodlawmedicineEdemaHumansGeneral DentistryDexamethasoneUNESCO:CIENCIAS MÉDICASAnti-inflammatory agentsintermaxillary fixationPain Postoperativeaccuracybusiness.industryorthognathic surgeryResearchTooth ImpactedKetorolacThird Molarintermediate splintOtorhinolaryngologyAnesthesiaTooth ExtractionSurgeryFemaleMolar ThirdTrismusSwellingmedicine.symptombone screwOral SurgerybusinessKetorolacmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study

2019

Background: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, characterized by progressive loss of spinal and cortical motor neurons, leading to muscular atrophy, respiratory failure, and ultimately death. There is no known cure, and the clinical benefit of the two drugs approved to treat ALS remains unclear. Novel disease-modifying therapeutics that are able to modulate the disease course are desperately needed. Our objective was to evaluate the efficacy and tolerability of Elysium Health's candidate drug EH301 in people with ALS (PALS). Methods: This was a single-center, prospective, double-blind, randomized, placebo-controlled pilot study. Thirty-two PALS we…

MaleVital CapacityPilot ProjectsGastroenterologylaw.inventionPlacebos0302 clinical medicineRandomized controlled triallawStilbenesMedicineAmyotrophic lateral sclerosisMedicamento1-(beta-D-Ribofuranosyl)nicotinamide chlorideMiddle AgedDrug CombinationsTreatment OutcomeNeurologyTolerabilityDisease ProgressionFemale35-Dimethoxy-4′-hydroxy-trans-stilbeneNiacinamidemedicine.medical_specialty3Investigación médicaPlaceboDouble blind03 medical and health sciencesAtrophyDouble-Blind MethodInternal medicinerandomized control studyHumansMuscle StrengthhumanAgedElectromyographybusiness.industryAmyotrophic Lateral Sclerosismedicine.diseaseAmyotrophic lateral sclerosis5-Dimethoxy-4 '-hydroxy-trans-stilbeneMétodo doble ciego1-(beta-D-Ribofuranosyl) nicotinamide chlorideRibonucleosidesNeurology (clinical)business030217 neurology & neurosurgeryEsclerosis amiotrófica lateral
researchProduct

Effect of nebulized beclomethasone on airway inflammation and clinical status of children with allergic asthma and rhinitis: a randomized, double-bli…

2012

We aimed to evaluate the therapeutic effect of nebulized beclomethasone dipropionate (nBDP) on both allergic asthma and rhinitis. In a randomized, double-blind, placebo-controlled study, 40 children (mean age 10.7 ± 2.1 years) with allergic asthma and rhinitis received either nBDP (daily dose of 800 µg, administered twice daily) or placebo for 4 weeks (with a face mask), after a 2-week run-in period of clinical assessment. Nasal and oral fractional exhaled nitric oxide (FeNO) measurements together with pulmonary function tests, nasal and oral exhaled breath condensate (EBC) collection for pH and interleukin-5 (IL-5) measurements as well as nasal and bronchial symptom scores were obtained at…

MaleVital capacityRhinitis Allergic PerennialAdolescentVisual analogue scaleImmunologyPlacebo-controlled studyPilot ProjectsPlaceboNitric OxidePulmonary function testingDouble-Blind MethodAdministration InhalationmedicineImmunology and AllergyHumansExhaled breath condensateAnti-Asthmatic AgentsChildAdrenergic beta-2 Receptor Agonistsrhinorrheabusiness.industryNebulizers and VaporizersBeclomethasoneGeneral MedicineImmunoglobulin EAsthmarespiratory tract diseasesRespiratory Function TestsBreath TestsAnesthesiaImmunologyExhaled nitric oxideFemalemedicine.symptomInterleukin-5businessbeclomethasone and asthma
researchProduct

A Double-Blind Randomized Controlled Trial (RCT) of Titanium-13Zirconium versus Titanium Grade IV Small-Diameter Bone Level Implants in Edentulous Ma…

2012

Background: The use of endosseous dental implants has become common practice for the rehabilitation of edentulous patients, and a two-implant overdenture has been recommended as the standard of care. The use of small-diameter implants may extend treatment options and reduce the necessity for bone augmentation. However, the mechanical strength of titanium is limited, so titanium alloys with greater tensile and fatigue strength may be preferable. Purpose: This randomized, controlled, double-blind, multicenter study investigated in a split-mouth model whether small-diameter implants made from Titanium-13Zirconium alloy (TiZr, Roxolid™) perform at least as well as Titanium Grade IV implants. Me…

MaleZIRCONIUM ALLOYSDentistrychemistry.chemical_elementMandiblelaw.inventionDouble-Blind MethodRandomized controlled triallawalloyDental Prosthesis DesignHumansJaw EdentulousMedicinebone level implantBone leveledentulous mandibleORAL-HEALTHAdverse effectGeneral DentistryAgedAged 80 and overTitaniumSUPPORTED OVERDENTURESbusiness.industrySPLIT-MOUTHDental Implantation EndosseousTitanium alloySoft tissueSUCCESSOSSEOINTEGRATED IMPLANTSMiddle Agedddc:617.6Treatment OutcomeDental Prosthesis Designchemistryddc:618.97DENTAL IMPLANTSFemaleImplantZirconiumOral Surgerydouble-blindLocatorbusinessFOLLOW-UPITI IMPLANTSRCTTitaniumClinical implant dentistry and related research
researchProduct

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct